Mark Bloch1,2, Jody Kamminga3, Avindra Jayewardene1,4, Michael Bailey5, Angela Carberry1,4, Trina Vincent1, Dick Quan1, Paul Maruff6, Bruce Brew2,7,8, Lucette A Cysique2,7,8,9. 1. Holdsworth House Medical Practice. 2. Faculty of Medicine, University of New South Wales. 3. Department of Psychology, Macquarie University. 4. Charles Perkins Centre, University of Sydney, New South Wales. 5. Monash University. 6. Psychology Department Melbourne University, Victoria. 7. St Vincent's Hospital. 8. St Vincent's Applied Medical Research Centre. 9. Neuroscience Research Australia, Sydney, New South Wales, Australia.
Abstract
BACKGROUND: Human immunodeficiency virus (HIV)-associated neurocognitive disorders (HAND) are not routinely assessed due to the lack of an adequate screening strategy. We aimed to develop a clinically relevant screening procedure for symptomatic HAND, validated against a gold standard neuropsychological (NP) test battery. METHODS: Representative HIV-infected (HIV+) and demographically matched HIV-uninfected (HIV-) participants in an observational study completed a standard evaluation for mood, drug and/or alcohol use, and activities of daily living and a newly designed 20-minute computerized CogState battery that assessed 5 cognitive domains. A subset completed standard NP assessment for 8 cognitive domains. HAND definition on screening and gold standard NP was determined using demographically corrected z scores and the global deficit score (≥ 0.5), applying the Frascati criteria. Participants were blinded to screening results, and the NP examiner was blinded to screening and HIV status. RESULTS: A total of 254 HIV+ participants were enrolled-mean age, 48.9 ± 10.2 years; median nadir CD4, 270 cells/mL; tertiary educated, 54%; and HIV- controls, 72. HIV+ HAND screening prevalence was 30.7% (HIV-associated dementia, 3.2%; mild neurocognitive disorder, 12.6%; and asymptomatic neurocognitive disorder, 15.0%; HIV- group: 13.9%; P = .004). Of the 75 participants who completed the NP battery, the HAND rate in the HIV+ group was 50.9% vs 43.4% by screening (P > .50). HAND screening vs gold standard NP sensitivity was 76% and specificity was 71%. Clinically relevant HIV-associated dementia and mild neurocognitive disorder sensitivity was 100% and specificity was 98% (positive predictive value 0.92). CONCLUSIONS: Symptomatic HAND warranting neurological review was accurately predicted using a CogState-based screening procedure.
BACKGROUND:Human immunodeficiency virus (HIV)-associated neurocognitive disorders (HAND) are not routinely assessed due to the lack of an adequate screening strategy. We aimed to develop a clinically relevant screening procedure for symptomatic HAND, validated against a gold standard neuropsychological (NP) test battery. METHODS: Representative HIV-infected (HIV+) and demographically matched HIV-uninfected (HIV-) participants in an observational study completed a standard evaluation for mood, drug and/or alcohol use, and activities of daily living and a newly designed 20-minute computerized CogState battery that assessed 5 cognitive domains. A subset completed standard NP assessment for 8 cognitive domains. HAND definition on screening and gold standard NP was determined using demographically corrected z scores and the global deficit score (≥ 0.5), applying the Frascati criteria. Participants were blinded to screening results, and the NP examiner was blinded to screening and HIV status. RESULTS: A total of 254 HIV+ participants were enrolled-mean age, 48.9 ± 10.2 years; median nadir CD4, 270 cells/mL; tertiary educated, 54%; and HIV- controls, 72. HIV+ HAND screening prevalence was 30.7% (HIV-associated dementia, 3.2%; mild neurocognitive disorder, 12.6%; and asymptomatic neurocognitive disorder, 15.0%; HIV- group: 13.9%; P = .004). Of the 75 participants who completed the NP battery, the HAND rate in the HIV+ group was 50.9% vs 43.4% by screening (P > .50). HAND screening vs gold standard NP sensitivity was 76% and specificity was 71%. Clinically relevant HIV-associated dementia and mild neurocognitive disorder sensitivity was 100% and specificity was 98% (positive predictive value 0.92). CONCLUSIONS: Symptomatic HAND warranting neurological review was accurately predicted using a CogState-based screening procedure.
Authors: Igor Grant; Donald R Franklin; Reena Deutsch; Steven P Woods; Florin Vaida; Ronald J Ellis; Scott L Letendre; Thomas D Marcotte; J H Atkinson; Ann C Collier; Christina M Marra; David B Clifford; Benjamin B Gelman; Justin C McArthur; Susan Morgello; David M Simpson; John A McCutchan; Ian Abramson; Anthony Gamst; Christine Fennema-Notestine; Davey M Smith; Robert K Heaton Journal: Neurology Date: 2014-05-09 Impact factor: 9.910
Authors: D V Sheehan; Y Lecrubier; K H Sheehan; P Amorim; J Janavs; E Weiller; T Hergueta; R Baker; G C Dunbar Journal: J Clin Psychiatry Date: 1998 Impact factor: 4.384
Authors: Lucette A Cysique; Robert K Heaton; Jody Kamminga; Tammy Lane; Thomas M Gates; Danielle M Moore; Emma Hubner; Andrew Carr; Bruce J Brew Journal: J Neurovirol Date: 2014-04-03 Impact factor: 2.643
Authors: Lisa Hopcroft; Laura Bester; Daniel Clement; Adria Quigley; Manisha Sachdeva; Sean B Rourke; Stephanie A Nixon Journal: J Int AIDS Soc Date: 2013-07-23 Impact factor: 5.396
Authors: Eugene L Asahchop; William G Branton; Anand Krishnan; Patricia A Chen; Dong Yang; Linglong Kong; Douglas W Zochodne; Bruce J Brew; M John Gill; Christopher Power Journal: JCI Insight Date: 2018-12-06
Authors: Benedetta Milanini; Robert Paul; Emmanuel Bahemana; Yakubu Adamu; Francis Kiweewa; Rither Langat; John Owuoth; Elaine Allen; Christina Polyak; Julie Ake; Victor Valcour Journal: AIDS Date: 2018-11-13 Impact factor: 4.177
Authors: Anna J Dreyer; Sam Nightingale; Jodi M Heaps-Woodruff; Michelle Henry; Hetta Gouse; Robert H Paul; Kevin G F Thomas; John A Joska Journal: J Neurovirol Date: 2021-07-09 Impact factor: 2.643
Authors: Ilex Beltran-Najera; Jennifer L Thompson; Anastasia Matchanova; Kelli L Sullivan; Michelle A Babicz; Steven Paul Woods Journal: Clin Neuropsychol Date: 2021-07-26 Impact factor: 3.535